Search and analyze individual stocks with comprehensive metrics

Wanbury Ltd

WANBURYPharmaceuticals
219.00+0.00 (+0.00%)
As on 15 Jan 2026, 04:33 amMarket Open

Fundamental Score

...

Wanbury Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Excellent

Return on Equity

76.52%
Excellent

Return on Capital Employed

36.68%
Poor

Operating Profit Margin (5Y)

9.18%
Poor

Dividend Yield

0.00%

Valuation Metrics

Excellent

Price to Earnings

20.82x

Market Capitalization

895.00 (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

1197.12%
Excellent

YoY Quarterly Sales Growth

24.46%
Average

Sales Growth (5Y)

10.29%
Excellent

EPS Growth (5Y)

27.81%
Excellent

Profit Growth (5Y)

30.94%

Financial Health

Poor

Debt to Equity

3.02x
Poor

Interest Coverage

2.14x
Good

Free Cash Flow (5Y)

29.50 (Cr)

Ownership Structure

Average

Promoter Holding

39.63%
Poor

FII Holding

0.80%
Poor

DII Holding

0.00%
Poor

Pledged Percentage

71.73%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
39.63%
Promoter Holding
895.00 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of WANBURY across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Strong Return on Equity (76.52%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (36.68%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Attractive Valuation (P/E: 20.82 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.

Robust Profit Growth (1197.12%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Strong Revenue Growth (24.46%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Excellent EPS Growth (27.81% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.

Strong Profit Growth Track Record (30.94% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Strong Cash Generation (₹29.50 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Risk Factors

7 factors identified

Elevated Debt Levels (D/E: 3.02)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.

Weak Interest Coverage (2.14x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.

Limited Institutional Interest (FII+DII: 0.80%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

High Share Pledging Risk (71.73%)

Observation: Significant promoter share pledging creates potential overhang.

Analysis: High pledging levels may create selling pressure during market downturns or margin calls.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High Debt-to-Equity Ratio

Observation: Elevated financial risk due to high leverage.

Analysis: High debt levels may strain cash flows and increase financial risk during economic downturns.

Very High Debt Levels

Observation: Excessive leverage may strain cash flows.

Analysis: Debt-to-equity above 2.0 indicates potential financial distress risk.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Wanbury Ltd

About WANBURY

Business Overview

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Company Details

Symbol:WANBURY
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mohan Kumar Rayana
Whole Time Director
Mr. Vinod R. Verma
Chief Financial Officer
Mr. Jitendra Jayantilal Gandhi
Compliance Officer & Company Secretary

Corporate Events

Recent
Ex-Dividend Date
2010-07-29

WANBURY Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)76.52%
Return on Capital Employed36.68%
Operating Profit Margin (5Y)9.18%
Debt to Equity Ratio3.02
Interest Coverage Ratio2.14

Growth & Valuation

Sales Growth (5Y)10.29%
Profit Growth (5Y)30.94%
EPS Growth (5Y)27.81%
YoY Quarterly Profit Growth1197.12%
YoY Quarterly Sales Growth24.46%

Frequently Asked Questions

What is the current price of Wanbury Ltd (WANBURY)?

As of 15 Jan 2026, 04:33 am IST, Wanbury Ltd (WANBURY) is currently trading at ₹219.00. The stock has a market capitalization of ₹895.00 (Cr).

Is WANBURY share price Overvalued or Undervalued?

WANBURY is currently trading at a P/E ratio of 20.82x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.

What factors affect the Wanbury Ltd share price?

Key factors influencing WANBURY's price include its quarterly earnings growth (Sales Growth: 24.46%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Wanbury Ltd a good stock for long-term investment?

Wanbury Ltd shows a 5-year Profit Growth of 30.94% and an ROE of 76.52%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 3.02 before investing.

How does Wanbury Ltd compare with its industry peers?

Wanbury Ltd competes with major peers in the Pharmaceuticals. Investors should compare WANBURY's P/E of 20.82x and ROE of 76.52% against the industry averages to determine its competitive standing.

What is the P/E ratio of WANBURY and what does it mean?

WANBURY has a P/E ratio of 20.82x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹21 for every ₹1 of annual earnings.

How is WANBURY performing according to Bull Run's analysis?

WANBURY has a Bull Run fundamental score of 37.6/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does WANBURY belong to?

WANBURY operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Wanbury Ltd.

What is Return on Equity (ROE) and why is it important for WANBURY?

WANBURY has an ROE of 76.52%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Wanbury Ltd generates profits from shareholders' equity.

How is WANBURY's debt-to-equity ratio and what does it indicate?

WANBURY has a debt-to-equity ratio of 3.02, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.

What is WANBURY's dividend yield and is it a good dividend stock?

WANBURY offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has WANBURY grown over the past 5 years?

WANBURY has achieved 5-year growth rates of: Sales Growth 10.29%, Profit Growth 30.94%, and EPS Growth 27.81%.

What is the promoter holding in WANBURY and why does it matter?

Promoters hold 39.63% of WANBURY shares, with 71.73% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is WANBURY's market capitalization category?

WANBURY has a market capitalization of ₹895 crores, placing it in the Small-cap category.

How volatile is WANBURY stock?

WANBURY has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for WANBURY?

WANBURY has a 52-week high of ₹N/A and low of ₹N/A.

What is WANBURY's operating profit margin trend?

WANBURY has a 5-year average Operating Profit Margin (OPM) of 9.18%, indicating the company's operational efficiency.

How is WANBURY's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 24.46% and YoY Profit Growth of 1197.12%.

What is the institutional holding pattern in WANBURY?

WANBURY has FII holding of 0.80% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.